POM-VPS Prescription Required

Covexin 10 Suspension for Injection for Sheep and Cattle

Active ingredients: Clostridium chauvoei, Clostridium haemolyticum, Clostridium novyi, Clostridium perfringens, Clostridium septicum, Clostridium sordellii, Clostridium tetani

Form

Injection

Species

Cattle Sheep

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5120

What it's used for

For the active immunisation of sheep and cattle against diseases associated with infections caused by Clostridium perfringens type A, C. perfringens type B...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Clostridium chauvoei + Clost...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Covexin 10 Suspension for Injection for Sheep and Cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For the active immunisation of sheep and cattle against diseases associated with
infections caused by Clostridium perfringens type A, C. perfringens type B,
type C, C. perfringens type D, Clostridium chauvoei, Clostridium novyi type B, Clostridium
septicum, Clostridium sordellii and Clostridium haemolyticum and against tetanus caused
by Clostridium tetani.
For the passive immunisation of lambs and calves against infections caused by the above
mentioned clostridial species (except C. haemolyticum in sheep).
Onset of immunity: 2 weeks after the basic vaccination course (as demonstrated by
serology only).
Duration of active immunity as demonstrated by serology only:
Sheep: 1 year against C. perfringens type A, B, C and D, C. novyi type B, C. sordellii
tetani
< 6 months against
Cattle: 1 year against C. tetani and C. perfringens type D
< 1 year against type A, B and C
< 6 months against
chauvoei
Additionally, an anamnestic humoral immune response (immunological memory) to all
components was demonstrated after antigen stimulation 1 year after the basic vaccination
course.
Duration of passive immunity as demonstrated by serology only:
Lambs:
At least 2 weeks for C. septicum and , at least 8 weeks for C. perfringens
type B and C. perfringens type C and at least 12 weeks for C. perfringens type A, C.
perfringens type D, C. novyi type B, C. sordellii
was observed for C. haemolyticum.
Calves:
At least 2 weeks for C. sordellii, and C. haemolyticum, at least 8 weeks for C.
septicumC. chauvoei and at least 12 weeks for C. perfringens type A, C.
perfringens type B, C. perfringens type C, C. perfringens type D, C. novyi
C. tetani.

Do not use in sick or immunodeficient animals.

Sheep and cattle:
Very common
(>1 animal / 10 animals treated):
Injection site swelling
1,2,6
, Injection
site induration
2,6
, Injection site
reaction
2,6
,
Hyperthermia
Common
(1 to 10 animals / 100 animals
treated):
Injection site abscess
, Injection site
skin discolouration
3,6
, Injection site
pain
4,6
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Anaphylactic-type reaction
1
Such a swelling may reach up to a mean value of 6 cm in diameter in sheep and 15 cm
(sometimes up to 25 cm) in diameter in cattle.
Most local reactions will resolve within 3-6 weeks in sheep and in less than 10 weeks in
cattle but may persist longer.
Returns to normal as the local reaction resolves.
For 1 – 2 days post first vaccination.
If such reaction occurs, appropriate treatment such as adrenaline should be administered
without delay.
The local reactions do not affect the general health, demeanour, feeding or weight gain of
the animals.

Revised: June 2024
AN: 04061/2022
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See also section 16 of the package leaflet for contact details.

Vaccinate healthy animals only.
The effectiveness of the vaccine in providing passive immunity to young lambs and calves
depends on these animals ingesting adequate amounts of colostrum on the first day of life.
Clinical trials have demonstrated that the presence of maternal antibodies, particularly
against C. perfringens type A (calves only), C. chauvoei (lambs

Revised: June 2024
AN: 04061/2022
only) and C. perfringens type D may reduce the antibody response to vaccination in young
lambs and calves. Therefore, to ensure an optimal response in young animals with high
levels of MDA, the basic vaccination should be delayed until the levels wane (which is after
about 8-12 weeks of age, see section 4.2).

Special precautions for use in animals
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
Other precautions
Not applicable.

No information is available on the safety and efficacy of this vaccine when used with any
other veterinary medicinal product. A decision to use this vaccine before or after any other
veterinary medicinal product therefore needs to be made on a case by case basis.

Store and transport refrigerated (2 °C – 8 °C).Do not freeze.
Keep the bottle in the outer carton.

Revised: June 2024
AN: 04061/2022
Protect from light.

C. chauvoei whole culture, inactivated meets Ph. Eur.
C. novyi toxoid 1.2 U
C. septicum toxoid 3.6 U
C. tetani toxoid 2.5 U
C. sordellii toxoid 0.8 U
C. haemolyticum toxoid 1

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.